# A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor

> **NCT05021367** · PHASE1 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 164 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** TQB3823 tablets

## Key facts

- **NCT ID:** NCT05021367
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-23
- **Primary completion:** 2025-02
- **Final completion:** 2025-10
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05021367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05021367, "A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05021367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*